Steve Orndorff on Medical Foods—Fallback Option for Elusive AD Drug Status?

COMMENT The premise of this article is the notion that companies are using the medical food route as a “fallback” or backup strategy if their drug compound fails in the clinic. As I will discuss below, this premise is flawed. I wish to point out that this was nev